Hypoglycemia  >>  BIAsp 30 (biphasic insulin aspart 30/70 biosimilar)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BIAsp 30 (biphasic insulin aspart 30/70 biosimilar) / Novo Nordisk
REACH , NCT01487798: Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes

Completed
4
170
Europe
biphasic human insulin 30, biphasic insulin aspart 30
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
11/03
11/03
2006-001938-41: Effect of Exenatide plus Metformin vs. Premixed Human Insulin Aspart plus Metformin on Glycemic Control and Hypoglycemia in Patients with Inadequate Control of Type 2 Diabetes on Oral Antidiabetic Treatment

Completed
4
488
Europe
Exenatide, Metformin, insulin aspart/protamin crystallised insulin aspart in the ratio 30/70, LY2148568, BYETTA, NovoMix 30, NovoMix 30 Flexpen, BYETTA, NovoMix 30, NovoMix 30 Flexpen
Lilly Deutschland GmbH
Type 2 Diabetes mellitus
 
 
2005-003824-21: Effects and comparisons of once & twice daily insulin’s in combination with oral hypoglycaemic agents on glycaemic control, hypoglycaemia and weight in type 2 Diabetes.

 
4
252
Europe
Lantus, Levemir, Novomix 30, Lantus, Levemir, NovoMix, Lantus, Levemir, NovoMix
Royal Liverpool University Hospital
Type 2 Diabetes
 
01/11
ChiCTR1900021970: Efficacy and safety of beinaglutide (formerly known as benaglutide) versus insulin aspart 30 as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin alone: a prospective, multi-centric, randomized, open-labeled, parallel-group study.

Recruiting
4
420
 
benaglutide plus metformin ;biphasic insulin aspart 30 plus metformin
Peking University People's Hospital; Shanghai Benemae Pharmaceutical Corporation, Shanghai Benemae Pharmaceutical Corporation
Type 2 Diabetes
 
 

Download Options